Close Menu
Home › Kura Oncology Garners Promising Data for T-cell Lymphoma Drug in Biomarker-Defined Population

Kura Oncology Garners Promising Data for T-cell Lymphoma Drug in Biomarker-Defined Population

Jun 14, 2019
|
Turna Ray
Premium

NEW YORK (GenomeWeb) – Kura Oncology this week presented data demonstrating that its drug tipifarnib had promising activity in patients with advanced T-cell lymphomas, particularly when they have certain CXCL12 pathway biomarkers.

Get the full story with
Premium Access

Only $95 for the
first 90 days*

Premium Access gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try Premium Access now.

You may already have institutional access!

Check if I qualify.

Already a Precision Oncology News or 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Oct
03
Featured Webinar

Streamlined and High-Precision Cancer Analysis Using an Automated NGS Workflow in the Reference Lab Setting

This webinar will provide an overview of how an international reference laboratory has implemented an automated next-generation sequencing workflow with custom panels for analyzing cancer samples.

Oct
10
Featured Webinar

Laboratory Validation of a Kit-Based Liquid Biopsy NGS Assay

This webinar will provide an overview of how a pathology laboratory validated a 77-gene next-generation sequencing-based liquid biopsy assay.

Oct
23
Featured Webinar

Single-Cell Methylation Profiling of Pediatric Tumors via a Unique NGS-based Approach

This webinar will illustrate how single-cell methylation sequencing can be applied to gain significant insight into epigenetic heterogeneity in disease states, advancing cancer research discoveries. 

Oct
24
Featured Webinar

Designing, Decoding & Delivering on Genetic Testing for Inherited Disease at Versiti

This webinar will tell the story of Versiti’s journey in transforming genetic testing from a manual to a digitized process. It will include detail on how the organization succeeded, pain points along the way, a novel approach to variant assessment, and future plans for the program.

What's Popular?

In Cancer

  1. European Labs Continue to Validate, Implement TMB, Facing Down Cutoff Discordance Concerns

    Premium

  2. Thermo Fisher Scientific, Eli Lilly to Develop CDx for RET Inhibitor

  3. Repare Therapeutics Using CRISPR to Develop Cancer Treatments for Synthetic Lethal Targets

    Premium

  4. Keytruda Plus Chemotherapy Extends Survival in NSCLC Patients Lacking PD-L1 Expression

  5. Roche's Tecentriq Demonstrates Survival Benefit in PD-L1 High NSCLC

Sponsorships

Privacy Policy.  Terms & Conditions.  Copyright © 2019 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.